Return to the full list of Biomarkers
Blood biomarker for mtDNA Damage
Method of Measurement (Pre-analytical Tools)
Blood/Plasma
Biomarker Measured
Genetic variation/DNA
Use
Diagnostic
Monitoring
Stage of Development
Clinical trials
Active vs Completed Trials
Active
Aim/Results
Identify blood tests that may help earlier diagnosis of Alzheimer's disease and detect the disease progression.
Target Population/ Population Being Studied
Alzheimer's disease patients
Length of Current Trial
1 day
Number of Trial Participants
60
Estimated Trial Completion
July 2019
What is Required from Patients
blood draw, mild discomfort, in clinic visits
What is Required from the Health System
phlebotomist, equipped lab (e.g., centrifuge), a way to measure the peptide (e.g., mass spectrometer, protein assay kit, ELISA, or western blot)
Sponsor
Duke University
“Blood Biomarker of Alzheimer's Disease (AD).” ClinicalTrials.gov. Accessed October 10, 2019. https://clinicaltrials.gov/ct2/show/NCT03340571?term=biomarker&recrs=abdf&cond=Alzheimer+Disease&rank=3